MA46339A - Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 - Google Patents
Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30Info
- Publication number
- MA46339A MA46339A MA046339A MA46339A MA46339A MA 46339 A MA46339 A MA 46339A MA 046339 A MA046339 A MA 046339A MA 46339 A MA46339 A MA 46339A MA 46339 A MA46339 A MA 46339A
- Authority
- MA
- Morocco
- Prior art keywords
- usp
- inhibitors
- cyanopyrrolidine derivatives
- activating
- derivatives activating
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616627.4A GB201616627D0 (en) | 2016-09-30 | 2016-09-30 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46339A true MA46339A (fr) | 2019-08-07 |
Family
ID=57571070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046339A MA46339A (fr) | 2016-09-30 | 2017-10-02 | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11084821B2 (fr) |
| EP (1) | EP3519412B1 (fr) |
| JP (1) | JP7084918B2 (fr) |
| CN (1) | CN109790169B (fr) |
| GB (1) | GB201616627D0 (fr) |
| MA (1) | MA46339A (fr) |
| WO (1) | WO2018060742A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (fr) | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | Dérivés de 1-cyano-pyrrolidine comme des inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
| WO2019071073A1 (fr) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibition de la peptidase 30 spécifique de l'ubiquitine |
| JP7399870B2 (ja) * | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための化合物 |
| ES2988920T3 (es) * | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| JP7434285B2 (ja) * | 2018-08-14 | 2024-02-20 | アムジエン・インコーポレーテツド | N-シアノ-7-アザノルボルナン誘導体及びその使用 |
| AU2019356011B2 (en) * | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| EP4157834B1 (fr) | 2020-05-28 | 2024-07-03 | Mission Therapeutics Limited | Dérivés de n-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluorométhyl)phényl)oxazole-2-carboxamide et les dérivés de oxadiazole correspondants en tant qu'inhibiteurs d'usp30 pour le traitement de dysfonctionnement mitochondrial |
| IL298710A (en) | 2020-06-04 | 2023-02-01 | Mission Therapeutics Ltd | N-cyanopyrrolidines with activity as USP30 inhibitors |
| KR20230022215A (ko) | 2020-06-08 | 2023-02-14 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애, 암 및 섬유증의 치료에 사용하기 위한 USP30 억제제로서 1-(5-(2-시아노피리딘-4-일)옥사졸-2-카보닐)-4-메틸헥사하이드로피롤로[3,4-b]피롤-5(1H)-카보니트릴 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| CN118834147A (zh) * | 2021-09-22 | 2024-10-25 | 杭州天玑济世生物科技有限公司 | 一类具有萘胺结构的小分子化合物及其应用 |
| WO2023099561A1 (fr) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | N-cyanopyrrolidines substituées ayant une activité en tant qu'inhibiteurs de l'usp30 |
| CN114877158B (zh) * | 2022-04-15 | 2023-06-23 | 四川轻化工大学 | 一种非开挖原位修复管道用内衬管表面改性方法 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001077073A1 (fr) | 2000-04-06 | 2001-10-18 | Merck Frosst Canada & Co. | Inhibiteurs de proteases a cysteine de type cathepsines |
| EP2152079A4 (fr) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Composés hétérocycliques et utilisations de ceux-ci |
| WO2009129370A1 (fr) * | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Inhibiteurs de la cathepsine c |
| CL2009000915A1 (es) | 2008-04-18 | 2010-04-16 | Glaxo Group Ltd | Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd). |
| AR071369A1 (es) | 2008-04-18 | 2010-06-16 | Glaxo Group Ltd | Compuesto de 1- ciano-3-pirrolidinil-n-sustituido-sulfonamida, su uso para preparar un medicamento util para tratar una enfermedad pulmonar obstructiva cronica y composicion farmaceutica que lo comprende |
| EP2565186A1 (fr) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine |
| CA2883480A1 (fr) * | 2012-09-17 | 2014-03-20 | F. Hoffmann-La Roche Ag | Inhibiteurs de l'usp30 et methodes d'utilisation |
| BR112015009624A2 (pt) | 2012-11-02 | 2017-11-14 | Pfizer | inibidores de tirosina cinase de bruton |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| PT3049417T (pt) | 2013-07-31 | 2019-01-24 | Merck Patent Gmbh | Piridinas, pirimidinas e pirazinas, como inibidores de btk e utilizações das mesmas |
| US9868736B2 (en) * | 2013-10-10 | 2018-01-16 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| RU2019131017A (ru) * | 2013-10-21 | 2019-11-25 | Мерк Патент Гмбх | Соединения гетероарила в качестве ингибиторов btk и их применение |
| GB201404987D0 (en) | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| WO2015179190A1 (fr) | 2014-05-19 | 2015-11-26 | Northeastern University | Inhibiteurs d'amidase acide (naaa) hydrolysant la n-acyléthanolamine et leur utilisation |
| WO2016004272A1 (fr) * | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| WO2016019237A2 (fr) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibiteurs de la tyrosine kinase de bruton |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| TN2017000158A1 (en) | 2014-10-24 | 2018-10-19 | Bristol Myers Squibb Co | Carbazole derivatives |
| PT3461821T (pt) * | 2014-10-24 | 2020-08-05 | Bristol Myers Squibb Co | Compostos de indol carboxamida úteis como inibidores de quinase |
| HRP20210791T2 (hr) * | 2015-03-30 | 2021-12-10 | Mission Therapeutics Limited | 1-cijano-pirolidin spojevi kao usp30 inhibitori |
| WO2016192074A1 (fr) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Inhibiteurs de la btk |
| CN107849013B (zh) | 2015-07-14 | 2022-03-29 | 特殊治疗有限公司 | 作为dub抑制剂用于治疗癌症的氰基吡咯烷类 |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) * | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| EP3433246B1 (fr) * | 2016-03-24 | 2022-05-04 | Mission Therapeutics Limited | Dérivés de 1-cyano-pyrrolidine comme des inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| CN110831936B (zh) | 2017-06-20 | 2023-03-28 | 特殊治疗有限公司 | 具有dub抑制剂活性的取代氰基吡咯烷 |
-
2016
- 2016-09-30 GB GBGB1616627.4A patent/GB201616627D0/en not_active Ceased
-
2017
- 2017-10-02 MA MA046339A patent/MA46339A/fr unknown
- 2017-10-02 CN CN201780060487.4A patent/CN109790169B/zh active Active
- 2017-10-02 WO PCT/GB2017/052949 patent/WO2018060742A1/fr not_active Ceased
- 2017-10-02 JP JP2019517227A patent/JP7084918B2/ja active Active
- 2017-10-02 EP EP17780195.8A patent/EP3519412B1/fr active Active
- 2017-10-02 US US16/336,202 patent/US11084821B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3519412B1 (fr) | 2021-12-01 |
| CN109790169A (zh) | 2019-05-21 |
| EP3519412A1 (fr) | 2019-08-07 |
| CN109790169B (zh) | 2022-03-29 |
| JP7084918B2 (ja) | 2022-06-15 |
| US20200199126A1 (en) | 2020-06-25 |
| JP2019532950A (ja) | 2019-11-14 |
| WO2018060742A1 (fr) | 2018-04-05 |
| US11084821B2 (en) | 2021-08-10 |
| GB201616627D0 (en) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| EP3416964A4 (fr) | Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| EP3687543A4 (fr) | Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
| EP3386981A4 (fr) | Hétérocycles utiles en tant qu'agents anticancereux | |
| MA53352A (fr) | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase | |
| MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| MA50655A (fr) | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA51133A (fr) | Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc | |
| EP3457851A4 (fr) | Dérivés de sobétirome | |
| EP3402793A4 (fr) | Dérivés de pyridazine en tant qu'activateurs d'eaat2 |